Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 2/20 | 0.33 |
| ▸ | GPR88 | Q9GZN0 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MITF | O75030 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29501778 | 1.00 | SLC6A3 (0.36) | SLC6A3TAS1R3TAS1R1SMN1; SMN2HTT | |
| SCHEMBL29047772 | 0.86 | HTT (0.35) | SMN1; SMN2HTTLMNA | |
| SCHEMBL29501742 | 0.86 | HTT (0.35) | SMN1; SMN2HTTLMNA | |
| SCHEMBL23680925 | 0.86 | HTT (0.35) | SMN1; SMN2HTTLMNA | |
| SCHEMBL23680918 | 0.79 | IDO1 (0.35) | SLC6A3HTTLMNARAB9A | |
| SCHEMBL23680931 | 0.79 | NR3C2 (0.34) | SLC6A3 | |
| SCHEMBL29501757 | 0.79 | IDO1 (0.35) | SLC6A3HTTLMNARAB9A | |
| SCHEMBL29501811 | 0.79 | NR3C2 (0.34) | SLC6A3 | |
| SCHEMBL23650016 | 0.78 | EGLN1 (0.39) | ACACB | |
| SCHEMBL23649986 | 0.76 | MCHR1 (0.39) | SMN1; SMN2ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210227826-A1 | Microbiocidal Picolinamide Derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210227826-A1 | Microbiocidal Picolinamide Derivatives | CASP2, CASP1, MSR1 | SLC6A3 3848/4885TAS1R3 675/4885TAS1R1 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.